A. Brian Davis - Jun 4, 2021 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role: Chief Financial Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: VRCA
Transactions as of: Jun 4, 2021
Transactions value $: $49,450
Form type: 4
Date filed: 6/7/2021, 08:41 AM
Next filing: Oct 20, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRCA	Common Stock	Purchase	$49.5K	+5K	+63.29%	$9.89	12.9K	Jun 4, 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.75 to $9.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.75 to $9.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.